Status:
COMPLETED
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
Lead Sponsor:
Second Xiangya Hospital of Central South University
Conditions:
Hypertrophic Obstructive Cardiomyopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiti...
Eligibility Criteria
Inclusion
- Male or female aged ≥ 18 years
- Drug-refractory symptomatic patients with HOCM
- Willing and able to give written informed consent
Exclusion
- Enrolled in another clinical study.
- Patient unable to tolerate lying flat for one hour
- Pregnant Or Lactating Women
- With other contraindications for receive stereotactic ablative radiotherapy
Key Trial Info
Start Date :
January 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04686487
Start Date
January 12 2021
End Date
November 1 2022
Last Update
November 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China, 410011